Zacks Investment Research downgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
Other research analysts also recently issued reports about the stock. JMP Securities reduced their target price on shares of AnaptysBio from $180.00 to $153.00 and set a buy rating for the company in a research report on Wednesday, August 15th. Royal Bank of Canada restated a hold rating and set a $84.00 price target on shares of AnaptysBio in a research note on Wednesday, August 8th. Cantor Fitzgerald assumed coverage on shares of AnaptysBio in a research note on Monday, August 27th. They set an overweight rating and a $124.00 price target on the stock. Wedbush restated an outperform rating and set a $138.00 price target on shares of AnaptysBio in a research note on Tuesday, September 18th. Finally, Stifel Nicolaus set a $127.00 price target on shares of AnaptysBio and gave the company a buy rating in a research note on Friday, September 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $130.90.
AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.13. On average, equities analysts expect that AnaptysBio will post -2.72 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Partner Investment Management L.P. lifted its stake in AnaptysBio by 82.8% in the 2nd quarter. Partner Investment Management L.P. now owns 1,709 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 774 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in AnaptysBio by 65.9% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,057 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 817 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in AnaptysBio in the 2nd quarter worth approximately $211,000. United Services Automobile Association lifted its stake in AnaptysBio by 27.9% in the 2nd quarter. United Services Automobile Association now owns 3,138 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 685 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in AnaptysBio by 28.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,335 shares of the biotechnology company’s stock worth $237,000 after purchasing an additional 743 shares in the last quarter.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Read More: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.